Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

OGEN
Oragenics Inc.
stock NYSEAMERICAN

Market Open
Aug 17, 2026 10:51:10 AM EDT
0.5400USD+1.163%(+0.0062)160,026
0.4600Bid   0.6300Ask   0.1700Spread
Pre-market
Aug 17, 2026 9:11:30 AM EDT
0.5301USD-0.525%(-0.0028)100
After-hours
0.00USD0.000%(0.00)0
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 26, 2022
07:37AM EST  Oragenics Announces Adjournment Of Annual Meeting Of Shareholders Due To Lack Of Quorum   RTTNews
Jan 10, 2022
03:44PM EST  US Health & Human Services Says, Starting Jan. 15, 2022, Individuals With Private Health Insurance/Group Health Plan Who Buy Over-The-Counter COVID Tests Will Have Costs Covered By Plan/Insurance   Benzinga
Jan 4, 2022
12:17PM EST  Mid-Day Market Update: Nasdaq Dips 250 Points; TherapeuticsMD Shares Surge   Benzinga
Jan 3, 2022
04:35PM EST  Oragenics Shares Spike Higher; Co Reports In Form 4 Filing Director Robert Koski Buys 1M Shares At Average Price Of $0.47/Share   Benzinga
Dec 20, 2021
08:13AM EST  Oragenics Extends Collaboration With National Research Council Of Canada To Develop Vaccine Against Omicron Variant   RTTNews
08:07AM EST  Oragenics Extends Collaboration With The National Research Council Of Canada To Develop Vaccine Against The Omicron Variant   Benzinga
Dec 9, 2021
08:00AM EST  Oragenics to Participate in Virtual Fireside Chat Hosted by Alliance Global Partners   Business Wire
Dec 8, 2021
08:00AM EST  Oragenics Co-Authors a Publication Describing the Dual Mechanism of Action of Lantibiotics   Business Wire
Dec 1, 2021
08:08AM EST  Oragenics Announces Positive COVID-19 Study Results Evaluating Multiple Formulations Of SARS-CoV-2 Vaccine Candidate   RTTNews
08:04AM EST  Oragenics Reports COVID-19 Challenge Study Results Evaluating Multiple Formulations Of Its SARS-CoV-2 Vaccine Candidate: 'Both formulations [in hamster model] generated robust immune responses and reduced the SARS-CoV-2 viral loads'   Benzinga
08:00AM EST  Oragenics Announces Positive COVID-19 Challenge Study Results Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate   Business Wire
Nov 23, 2021
08:37AM EST  Oragenics Announces Adjournment Of Annual Meeting Of Shareholders Due To Lack of Quorum   Benzinga
Oct 26, 2021
06:03AM EDT  The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 05.45 A.M. EDT).   RTTNews
Oct 4, 2021
07:39AM EDT  Oragenics Awarded A $250,000 Grant From The National Institute Of General Medical Sciences For The Continued Research And Development Of Lantibiotics   Benzinga
07:34AM EDT  Oragenics Awarded $250,000 Grant From NIGMS For The Continued Research And Development Of Lantibiotics   RTTNews
07:30AM EDT  Oragenics Awarded a $250,000 Grant from the National Institute of General Medical Sciences (NIGMS) for the Continued Research and Development of Lantibiotics.   Business Wire
Sep 24, 2021
04:32PM EDT  UPDATE: Oragenics Says Will Focus On Continuing Independent Research, Development Efforts Relative To Lantibiotics In Order To Identify New Compounds To Pursue   Benzinga
04:31PM EDT  Oragenics Says On Sept. 22, Co, Eleszto Genetika, Mutually Terminated Lantibiotic ECC Agreement Dated Mar. 1, 2021, Says Will Cease Pre-Clinical Development Of It's Product Candidate OG716, Other Compounds Covered By Lantibiotic ECC   Benzinga
Sep 15, 2021
11:01AM EDT  Oragenics Launches Animal Study For COVID-19 Vaccine Candidate   Benzinga
07:34AM EDT  Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations Of SARS-CoV-2 Vaccine Candidate   RTTNews
07:30AM EDT  Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations Of Its SARS-CoV-2 Vaccine Candidate   Benzinga
Aug 30, 2021
07:34AM EDT  Oragenics Announces The Stabilized Pre-Fusion Spike Protein Trimer Produced By Its Canadian Collaborator And Licensed By The Company From The National Institutes Of Health Generates Neutralizing Antibodies In Mice After Immunization Against SARS-CoV-2   Benzinga
07:30AM EDT  Oragenics' SARS-CoV-2 Spike Protein Produces Neutralizing Antibodies in Mice with Intramuscular and Intranasal Adjuvants   Business Wire
Aug 24, 2021
07:33AM EDT  Oragenics Announces Postponement Of Annual Meeting Of Shareholders Due To Lack Of Quorum   RTTNews
07:30AM EDT  Oragenics Announces Postponement of Annual Meeting of Shareholders   Business Wire
Jul 27, 2021
02:33PM EDT  Mid-Afternoon Market Update: Nasdaq Tumbles 240 Points; Oragenics Shares Spike Higher   Benzinga
12:28PM EDT  Mid-Day Market Update: GasLog Partners Drops After Q2 Results; EyeGate Pharmaceuticals Shares Jump   Benzinga
11:13AM EDT  The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts   Benzinga
11:13AM EDT  Oragenics Enters Licensing Agreement With National Research Council Of Canada To Pursue Development Of SARS-CoV-2 Vaccines   Benzinga
Jul 1, 2021
07:01AM EDT  Oragenics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum   Business Wire
May 18, 2021
09:33AM EDT  Oragenics Believes Existing Cash And Cash Equivalents will Fund Operating Plan Into Q3 Of 2022   RTTNews
07:39AM EDT  Oragenics Issues Letter To Shareholders   Benzinga
May 3, 2021
07:37AM EDT  Alan Joslyn Resigns As CEO, President And Director Of Oragenics To Pursue Other Opportunities   RTTNews
07:30AM EDT  Oragenics Announce Changes in Management and Board of Directors   Business Wire
Apr 14, 2021
10:31AM EDT  OGEN: COVID-19 Vaccine Candidate Exhibits Protective Immunity in   Benzinga
Mar 9, 2021
12:10PM EST  Oragenics' COVID-19 Related Deal Pushes The Stock Higher   Benzinga
09:16AM EST  Oragenics Enters into Material Transfer Agreement With Biodextris For The Use Of Mucosal Adjuvant In Its Intranasal COVID-19 Vaccine; Financial Details Not Disclosed   Benzinga
07:12AM EST  Oragenics Enters Material Transfer Agreement With Biodextris For Mucosal Adjuvant For Intranasal COVID-19 Vaccine   RTTNews
07:00AM EST  Oragenics Enters into Material Transfer Agreement with Biodextris for Mucosal Adjuvant for Intranasal COVID-19 Vaccine   Business Wire
Mar 8, 2021
08:45AM EST  Oragenics to Participate in Two Investment Conferences During March   Business Wire
Feb 12, 2021
08:00AM EST  Oragenics Announces Recent Capital Raise and Warrant Exercises Totaling $21.9 Million and the Redemption of Its Series C Preferred Stock   Business Wire
Feb 2, 2021
08:04AM EST  Oragenics Announces Spike Protein Cov-2 S-2P Created By The NIH And Licensed By The Company Demonstrates Protective Immunity In Immunized Mice Challenged With Mouse-adapted Sars-CoV-2 Virus   Benzinga
08:01AM EST  SARS-CoV-2 Spike Protein Licensed by Oragenics from the NIH Demonstrates Protective Immunity in Mice   Business Wire
Jan 14, 2021
07:16AM EST  Oragenics Says Optimistic That Terra CoV-2 Vaccine Will Ultimately Prove To Have Several Advantages   RTTNews
07:05AM EST  Oragenics Issues Letter To Stockholders   Benzinga
Jan 7, 2021
03:14PM EST  Mid-Afternoon Market Update: Dow Rises 250 Points; 3D Systems Shares Spike Higher   Benzinga
07:30AM EST  Oragenics, Inc. (OGEN) has entered into a material transfer agreement with Adjuvance Technologies Inc. for use of the adjuvant TQL1055 in the company's Terra CoV-2 vaccine against COVID-19. The agreement calls for TQL1055 to be used in pre-clinical animal studies.   RTTNews
07:18AM EST  Oragenics Enters Into Material Transfer Agreement With Adjuvance Technologies For Use Of Adjuvant TQL1055   RTTNews
07:03AM EST  Oragenics Enters Into Material Transfer Agreement With Adjuvance Technologies For COVID-19 Vaccine Adjuvant   Benzinga
Dec 29, 2020
04:00PM EST  Oragenics Announces Closing of $6.5 Million Registered Direct Offering   Business Wire
Dec 24, 2020
08:32AM EST  Oragenics, Inc. Announces $6.5M Registered Direct Offering   Benzinga
08:30AM EST  Oragenics, Inc. Announces $6.5 Million Registered Direct Offering   Business Wire
Nov 24, 2020
11:37AM EST  Oragenics Announces Closing of $6.0 Million Underwritten Public Offering   Business Wire
Nov 20, 2020
02:33PM EST  Mid-Afternoon Market Update: Dow Drops Over 100 Points; Mesoblast Shares Spike Higher   Benzinga
12:37PM EST  Mid-Day Market Update: Nasdaq Edges Higher; Nano Dimension Shares Plunge   Benzinga
08:32AM EST  Oragenics Prices $5.25M Offering Of 14.189M Shares At $0.37/Share   Benzinga
08:30AM EST  Oragenics Prices $5.25 Million Common Stock Offering   Business Wire
Nov 19, 2020
05:14PM EST  CORRECTING AND REPLACING Oragenics Announces Proposed Underwritten Public Offering   Business Wire
04:23PM EST  Organics Announces Proposed Underwritten Public Offering; No Terms Disclosed   Benzinga
04:22PM EST  Organics Announces Proposed Underwritten Public Offering   Business Wire
Oct 6, 2020
10:35AM EDT  Why Oragenics Stock Is Trading Higher Today   Benzinga
08:11AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Tuesday, Oct. 6, 2020: DPZ, AZYO, OGEN, ALKS, AN   Benzinga
07:31AM EDT  FDA Broadly Supports Oragenics' Pre-IND Development Program for its SARS-CoV-2 Vaccine; Re-Affirms Plan to File IND Application by the End of 1Q21, Begin Phase 1 Study in Early 2Q21   Benzinga
07:30AM EDT  FDA Broadly Supports Oragenics' Pre-IND Development Program for its SARS-CoV-2 Vaccine   Business Wire
Sep 28, 2020
08:06AM EDT  Oragenics Provides An Update On Funding For Its SARS-CoV-2 Vaccine   RTTNews
07:32AM EDT  Oragenics Says Has Been Informed Of BARDA's Determination Not To Enter Negotiation With Co.; Says 'a combination of factors, including availability of funds, precluded the agency from entering into negotiations at this time.'   Benzinga
07:30AM EDT  Oragenics Provides an Update on Funding for its SARS-CoV-2 Vaccine   Business Wire
07:30AM EDT  Oragenics Shares Halted News Pending   Benzinga
Sep 11, 2020
07:30AM EDT  Oragenics Inc. to Present at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference   Business Wire
Aug 20, 2020
08:37AM EDT  Oragenics Signs Process Development and Manufacturing Agreement With Avid Bioservices for Coronavirus Vaccine   Benzinga
08:33AM EDT  Oragenics And Avid Bioservices Enter Process Development And drug Substance Manufacturing Agreement   RTTNews
08:30AM EDT  Oragenics Signs Process Development and Manufacturing Agreement With Avid Bioservices for Coronavirus Vaccine   Business Wire
Jul 22, 2020
07:52AM EDT  Oragenics Inc. (OGEN) said that the National Institutes of Health created stabilized pre-fusion spike protein (CoV-2 S-2P) licensed by the company has generated neutralizing antibodies in mice during immunization against SARS-CoV-2, the virus that causes COVID-19.   RTTNews
07:38AM EDT  Oragenics: Study Shows SARS-CoV-2 Spike Protein Licensed By Company From NIH Produces Neutralizing Antibodies   RTTNews
07:35AM EDT  Oragenics Says Preclinical Study Shows SARS-CoV-2 Spike Protein Licensed By Co. From NIH Produces Neutralizing Antibodies   Benzinga
07:30AM EDT  Preclinical Study Shows SARS-CoV-2 Spike Protein Licensed by Oragenics from the NIH Produces Neutralizing Antibodies   Business Wire
Jul 14, 2020
05:11AM EDT  80 Biggest Movers From Yesterday   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC